Status:
ENROLLING_BY_INVITATION
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
Beijing Anzhen Hospital
West China Hospital
Conditions:
Aortic Dissection
Aortic Dissection Aneurysm
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of S...
Eligibility Criteria
Inclusion
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
- The patients' age between 18 \~90 years old.
- Agree to participate in the study and sign the informed consent.
Exclusion
- Patients allergic to Thymosin α1 or Ulinastatin;
- Lactating women and pregnant women;
- Patients with mental diseases, drug and alcohol dependence;
- Refuse to participate in this study and refuse to sign the informed consent.
Key Trial Info
Start Date :
April 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06966687
Start Date
April 1 2025
End Date
December 31 2026
Last Update
May 13 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
2
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
3
Shanghai East Hospital Tongji University
Shanghai, Shanghai Municipality, China
4
West China Hospital
Chengdu, Sichuan, China